论文部分内容阅读
目的观察高/低转移人肝癌细胞株MHCC97-H/L是否存在侧群(SP)细胞并鉴定其致瘤性。方法MHCC97-H/L予Hoechst33342和羟基荧光素二醋酸盐琥珀酰亚胺脂(CFSE)荧光染色;流式细胞分选MHCC97-H/L中SP细胞,分选后细胞皮下接种非肥胖性糖尿病联合免疫缺陷(NOD/SCID)小鼠,观察成瘤情况。结果Hoechst33342和CFSE染色结果显示,MHCC97-H/L中未染色细胞分别为(4.02±0.02)%/(1.02±0.01)%,流式细胞分选结果示MHCC97-H/L中SP细胞为(4.88±0.66)%/(0.88±0.36)%,比例差异有统计学意义(P<0.05)。体内成瘤实验显示,SP细胞只需1×10~4个即可在NOD/SCID小鼠皮下成瘤(5/6),而1×10~6个非SP细胞均未成瘤(0/6)。结论高/低转移人肝癌细胞株MHCC97-H/L中均存在SP细胞亚群,但前者比例显著高于后者。肝癌SP细胞具有极高的致瘤性,并可能和肝癌转移潜能相关。
Objective To observe the presence or absence of side population (SP) cells in MHCC97-H / L hepatoma cell line with high / low metastasis and to identify its tumorigenicity. Methods MHCC97-H / L cells were stained with Hoechst 33342 and CFSE. Flow cytometry was used to identify the SP cells in MHCC97-H / L cells. The cells were subcutaneously inoculated with non-obese Diabetes combined immunodeficiency (NOD / SCID) mice were observed tumor formation. Results The results of Hoechst 33342 and CFSE staining showed that the number of unstained cells in MHCC97-H / L was (4.02 ± 0.02)% / (1.02 ± 0.01)%, respectively. The results of flow cytometry showed that the number of SP cells in MHCC97-H / 4.88 ± 0.66% / (0.88 ± 0.36)% respectively, the difference was statistically significant (P <0.05). The in vivo tumorigenicity test showed that the number of SP cells was 1 × 10 ~ 4 subcutaneously (5/6) in NOD / SCID mice, and none of 1 × 10 ~ 6 non-SP cells ). Conclusion The SP cell subsets were found in MHCC97-H / L human hepatoma cell line with high / low metastasis, but the proportion of the former was significantly higher than the latter. Liver cancer SP cells have very high tumorigenicity and may be related to the metastatic potential of liver cancer.